GB1587089A - Poly-ether antibiotics - Google Patents
Poly-ether antibiotics Download PDFInfo
- Publication number
- GB1587089A GB1587089A GB15258/78A GB1525878A GB1587089A GB 1587089 A GB1587089 A GB 1587089A GB 15258/78 A GB15258/78 A GB 15258/78A GB 1525878 A GB1525878 A GB 1525878A GB 1587089 A GB1587089 A GB 1587089A
- Authority
- GB
- United Kingdom
- Prior art keywords
- antibiotic
- tmb
- agar
- alkali metal
- antibiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims description 18
- 229940088710 antibiotic agent Drugs 0.000 title description 15
- 239000004721 Polyphenylene oxide Substances 0.000 title description 5
- 230000003115 biocidal effect Effects 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 11
- 241001600133 Streptomyces ribosidificus Species 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 229910052783 alkali metal Inorganic materials 0.000 claims description 9
- -1 alkali metal salts Chemical class 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 159000000000 sodium salts Chemical class 0.000 description 17
- 229920001817 Agar Polymers 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000008272 agar Substances 0.000 description 15
- 239000002609 medium Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 210000004215 spore Anatomy 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- BKZOUCVNTCLNFF-IGXZVFLKSA-N (2s)-2-[(2r,3r,4s,5r,6s)-2-hydroxy-6-[(1s)-1-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-[(2r,3s,4r,5r)-5-[(2s,3s,4s,5r,6s)-6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl]-4-methoxy-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,8-dimethyl-1,10-dioxaspiro[4.5]dec Chemical compound O([C@@H]1[C@@H]2O[C@H]([C@@H](C)[C@H]2OC)[C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](OC)C3)[C@@H](C)[C@@H]3[C@@H]([C@H](OC)[C@@H](C)[C@](O)([C@H](C)C(O)=O)O3)C)CC2)[C@](C)(O)[C@H](C)[C@@H](OC)[C@@H]1C BKZOUCVNTCLNFF-IGXZVFLKSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 208000003495 Coccidiosis Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010023076 Isosporiasis Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 159000000001 potassium salts Chemical class 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 240000007165 Eragrostis tenella Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- BKZOUCVNTCLNFF-UHFFFAOYSA-N Lonomycin Natural products COC1C(C)C(C2(C)OC(CC2)C2(C)OC3(OC(C(C)C(OC)C3)C(C)C3C(C(OC)C(C)C(O)(C(C)C(O)=O)O3)C)CC2)OC1C1OC(C)(O)C(C)C(OC)C1C BKZOUCVNTCLNFF-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 3
- 230000001165 anti-coccidial effect Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000006877 oatmeal agar Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000013587 production medium Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- QZVSDERYSHAHPU-LFEMCTADSA-N (2r)-2-[(2s,3r,4s,5s,6s)-2-hydroxy-6-[[(2r,3r,4r,5s,6r,7r,9s)-2-[(5s)-5-[(2r,5r)-5-[(3s,5r,6s)-6-hydroxy-3,5,6-trimethyloxan-2-yl]oxolan-2-yl]oxolan-2-yl]-3,7-dimethoxy-2,4,6-trimethyl-1,10-dioxaspiro[4.5]decan-9-yl]methyl]-4-methoxy-5-[(2s,5s,6r)-5-metho Chemical compound C1([C@H]2CC[C@@H](O2)[C@@H]2CCC(O2)[C@@]2(C)O[C@]3([C@H](C)[C@H]2OC)[C@@H]([C@H](OC)C[C@@H](C[C@H]2[C@]([C@@H](OC)[C@@H](C)[C@@](O)([C@@H](C)C(O)=O)O2)(C)O[C@@H]2O[C@H](C)[C@@H](OC)CC2)O3)C)O[C@](C)(O)[C@H](C)C[C@@H]1C QZVSDERYSHAHPU-LFEMCTADSA-N 0.000 description 2
- BBBFYZOJHSYQMW-LGDQNDJISA-N (2s)-2,4-diamino-4-oxobutanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O BBBFYZOJHSYQMW-LGDQNDJISA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000223932 Eimeria tenella Species 0.000 description 2
- 235000019733 Fish meal Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- QZVSDERYSHAHPU-UHFFFAOYSA-N Septamycin Natural products COC1C(C)C2(C(C(OC)CC(CC3C(C(OC)C(C)C(O)(C(C)C(O)=O)O3)(C)OC3OC(C)C(OC)CC3)O2)C)OC1(C)C(O1)CCC1C(O1)CCC1C1OC(C)(O)C(C)CC1C QZVSDERYSHAHPU-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000002814 agar dilution Methods 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229940124536 anticoccidial agent Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003224 coccidiostatic agent Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000004467 fishmeal Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 210000003250 oocyst Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- UQZSVIGPZAULMV-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)[C@@H](N)CC(N)=O UQZSVIGPZAULMV-DKWTVANSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadexā¢ Substances 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 235000019742 Vitamins premix Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- AYTGUZPQPXGYFS-UHFFFAOYSA-N urea nitrate Chemical class NC(N)=O.O[N+]([O-])=O AYTGUZPQPXGYFS-UHFFFAOYSA-N 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Description
(54) IMPROVEMENTS IN AND RELATING TO POLY-ETHER
ANTIBIOTICS
(71) We, TAISHO PHARMACEUTICAL CO. LTD., a Japanese Corporation organised and existing under the laws of Japan, 6f 24-1, Takata 3-chome,
Toshimaku, Tokyo, Japan, do hereby declare the invention for which we pray that a patent may be granted to us and the method by which it is to be performed to be particularly described in and by the following statement:- The present invention relates to poly-ether anitbiotics and has particular reference to antibiotic TMB-481 which is a novel compound of a group of polyether antibiotics which have four methoxy groups. Examples of compounds of this group include A-28695A (U.S. Patent No. 3,839,558), septamycin [J. Antibiotics, 28 854 (1975)], TMH81 (lonomycin) (U.S. Patent No. 3,950,514), DE-3936 [J.
Antibiotics, 29, 91 (1976)], 31559RP (emericid) (U.K. Patent No. 1,495,858) and
A-218 [J. Antibiotics, 29, 10 (1976)].
Among them, antibiotic TM-481 is identified with DE-3936 and 31559RP, different from A-218 in terms of its molecular formula, and also different from septamycin which is identified with A-28695A in terms of whole structures and physico-chemical properties.
Antibiotic TMB-481 of this invention has the same structural formula as that of antibiotic TM-481. Antibiotic TMB-481, however, is different from antibiotic
TM-481 as compared with their physico-chemical properties such as melting point, specific rotation, Rf value on thin layer chromatogram and spectrum of 13C-NMR. Antibiotic TMB481, therefore, is elucidated to be a novel compound of a group of polyether antibiotics.
This invention relates to a novel antibiotic TMBW81 and its alkali metal salts, and to a method for the preparation thereof.
More particularly, this invention is concerned with a novel antibiotic
TMB-481 represented by the formula
and its alkali metal salts, derived from a strain of microorganism Streptomyces ribosidificus TM-481, and concerned with a process for the preparation of said novel antibiotics.
The antibiotics of this invention exhibit anticoccidial activity and are highly effective in controlling coccidiosis in poultry.
The antibiotics of this invention also exhibit antibiotic activity against pathogenic microorganisms. Especially, these antibiotics are useful for inhibition against Treponema hyodysenteria which causes swine dysentery.
Furthermore, the' antibiotics of this invention show lower toxicity than antibiotic TM "81.
Following is a description with reference to the accompanying drawings of methods of carrying the invention into effect.
In the drawings: Figure 1 shows the ultra violet absorption spectrum of antibiotic TMB--481 sodium salt in methanol.
Figure 2 shows the infrared absorption spectrum of antibiotic TMB--481 sodium salt with tablet of KBr.
Figure 3 shows the nuclear magnetic resonance spectrum of antibiotic TMB "81 sodium salt in deuterochloroform.
The antibiotics of this invention can be prepared by the cultivation, under controlled conditions, of a strain of Streptomyces ribosidificus TM-481 (ATCC No.
31,051) mentioned in the specification of U.S. Patent No. 3,950,514 concerning antibiotic TM-481.
The microbiological properties of the strain, Streptomyces ribosidificus
TM-481 are as follows: 1. General morphological findings
A mycelium is formed with the display of slight curved hyphae on glucoseasparagine agar medium although deveiopment of aerial mycelium is poor. But aerial mycelia on oatmeal agar, yeast extract-malt extract agar or starch agar medium form abundant spores.
Microscopic examination of the cultures grown on yeast extract-malt extract agar reveals branched filaments and spore chains forming spiral. Mature spore chains generally contain about 10 spores per chain. Electron micrograph of the spore shows oval to spherical form (0.7-1.0 x 1.0-1.4 ) with spiny surface.
2. Cultural characteristics
The cultural characteristics of Streptomyces ribosidificus TM--481 are listed in
Table 1.
TABLE 1
Cultural characteristics of Streptomyces ribosidificus TM-481
Medium Growth Aerial Mycelium Soluble Pigment Sucrose-nitrate Poor, yellowish Poor, pale yellow None agar cream to yellowish green Glucose-asparagine Poor, colorless to Powdery, grayish None, pale yellow agar yellowish cream brown after 2 weeks Glycerol-asparagine Good, yellowish White to light gray None agar cream or yellowish green Starch agar Good, yellowish Abundant, pale None cream to light yellowish green to gray dark grey Tyrosine agar Good, yellowish Abundant, white to None cream light gray or pale yellowish green Nutrient agar. Poor, colony shape, None None yellowish cream Yeast extract-malt Good, grayish yellow Abundant, pale None extract agar to yellowish green yellowish green to dark gray Oatmeal agar Good, yellowish Abundant, yellowish None cream to light gray green to dark gray All cultures were incubated at 30 C.
3. Physiological properties
The physiological properties of this strain are as follows:
Growth temperature range: 15-450C on oatmeal agar,
Optimal growth temperature: 30--35"C, Liquefaction of gelatin: slightly positive around the growth in 5-7 days at 20"C, Hydrolysis of starch: positive,
Coagulation of skimmed milk: negative,
Peptonization of skimmed milk: negative at 300C, positive at 370 C, Melanin production: negative,
Liquefaction of Loeffler's coagulated serum: positive,
and
Reduction of nitrate: positive.
Carbon source utilization test by method of Pridham and Gottlieb shows that this strain is able to utilize moderately or well D-glucose, L-arabinose, D-fructose, sucrose, inositol, rhamnose, ratfinose, and D-mannitol, but not at all D-xylose.
From the above results, the microbiological characteristics of this strain may be summarized as follows:
The strain TM--481 forms aerial mycelium with spiral and spore surface is spiny. Growth on synthetic media is poor and mycelium is yellowish cream to yellowish green. Soluble pigment is not generally observed but the culture on glucose-asparagine agar medium produces pale yellow soluble pigment. Cultures on organic media show good growth with yellowish cream to yellowish green color and abundant spore formation. But soluble pigment is not produced on the media.
This strain has been deposited to the Institute for Microbiological Industry and Technology, Japan, as FERM-P No. 2267, and at American Type Culture
Collection, Rockville, Maryland as ATCC No. 31051.
Antibiotic TMB481 is usually obtainable by inoculating an aqueous nutrient medium with a culture of the strain of Streptomyces ribosidificus To481, culturing said strain by the shaking culture method or aerated submerged culture method and separating the thus produced antibiotic TMB481 from the culture medium.
As well as the media in which other microorganisms are grown for the production of antibiotics, the nutrient medium for culturing the strain TM--481 usually contains sources of assimilable carbon and nitrogen. As sources of assimilable carbon, various carbohydrates such as ordinary starch, glycerol and sugars, for example, glucose and sucrose are preferably used. Various lipids and vegetable or animal oil may be used for the same object. Suitable sources of assimilable nitrogen include a wide variety of substances such as peptone, amino acids, casein, fish meal, soya bean meal, meat extract, yeast extract and various other nitrogenous substances of vegetable or animal origin. Chemicals such as urea nitrates and ammonium compounds may also be added to the nutrient media as a nitrogen source. Corn steep liquor, because of the wide variety of both organic and inorganic substances contained therein, is a valuable additive to the fermentation media. In some cases, essential mineral salts such as sodium chloride or antifoam may be added also.
The pH value of the medium is brought substantially to neutrality before sterilization, preferably to about pH 7. Fermentation is preferably carried out at a temperature of 28--35"C. The development of the culture is comparatively rapid, and so it can be observed that the active substance was produced in the culture media after 30 hours under suitable aerated submerged culture condition. The maximum production of antibiotic TMB1181 is usually attained after 48-72 hours in jar fermentation.
The fermentation medium is basified with an alkali metal base such as sodium hydroxide and potassium hydroxide, and centrifuged to separate a broth and a mycelium. The broth is extracted with a water-immiscible organic solvent such as ethyl acetate, benzene and chloroform and the mvcelium is extracted with a watermiscible organic solvent such as acetone and methanol. These extracts are combined, and then concentrated to dryness to give a crude antibiotic mixture.
Antibiotic TMB481 mixed sodium and potassium salts is separated from the crude antibiotic mixture and further purified by the efficient combination of silica gel column chromatography, gel filtration on Sephadex (Registered Trade Mark).
LH--20, and crystallization from a n-hexane-benzene solution.
In order to obtain the free acid of antibiotic TMB--481, antibiotic TMB--481 mixed sodium and potassium salts is dissolved in an organic solvent such as acetone and methyl ethyl ketone, and then acidified with an acid such as hydrochloric acid.
After addition of water, the mixture is extracted with ethyl acetate, benzene or chloroform to give the desired objective compound.
In order to obtain an alkali metal salt of antibiotic TMB48l, the free acid of antibiotic TMB-481 is dessolved in an organic solvent such as acetone and methyl ethyl ketone. To the resulting solution, an alkali metal base such as sodium hydroxide and potassium hydroxide is added. After addition of water, the solution is extracted with ethyl acetate, benzene or chloroform to give an alkali metal salt of antibiotic TMB-481.
Antibiotic TMB481 sodium salt obtained as described above has the following physico-chemical properties: (1) Appearance
Colorless needle (2) Elemental Analytical Values
C: 62.16, H: 8.81, Na: 2.60% (3) Molecular Weight
850 (4) Molecular Formula C44H75O14Na (5) Melting Point
181-182 C (6) Specific Optical Rotation [] 2D5 = +48.20 (C = 0.5%, methanol) (7) Ultara Violet Absorption Spectrum
Antibiotic TMB--481 sodium salt dissolved in methanol shows only end
absorption as shown in Fig. 1.
(8) Infrared Absorption Spectrum
The infrared absorption spectrum determined with tablet of KBr illustrated in
Fig. 2 shows characteristic bands at 3380, 3180, 2960, 2920, 2865, 2810, 2580, 1585, 1450, 1400, 1385, 1375, 1355, 1330, 1305, 1290, 1260, 1240, 1200, 1165, 1105, 1090, 1075, 1055, 1040,1015, 1000, 970,965,940,915,890, 870,855,825,790,745, and 700 cm-'.
(9) Nuclear Magnetic Resonance Spectrum
The nuclear magnetic resonance spectrum at 60 MHz of antibiotic TM B48 1 sodium salt in CDCI3 shows the characteristic four singlets at a 3.25-3.S2 which mean four methoxy groups (Fig. 3).
(10) Solubility
Antibiotic TMB--481 sodium salt is soluble in methanol, ethanol, butanol, acetone, ethyl acetate, chloroform, ethyl ether, benzene, n-hexane and petroleum ether, but practically insoluble in water.
(11) Color reaction
Antibiotic TMB=48l sodium salt gives positive reaction with iodine, potassium permanganate and vanillin-sulfuric acid, but negative reaction with ninhydrin, Molisch and ferric chloride.
The acute toxicity of antibiotic TMB-481 sodium salt, administrated orally to ddY mice(male, 5-week-old) and expressed as LD50 is 150 mg/kg. The toxicity of antibiotic TMB-481 is lower than that of antibiotic TM-481(LD50: 48 mg/kg) coproduced from said microorganism.
Antibiotic TMB=481 and the salts thereof can be used as the anticoccidial agent. For the control of coccidiosis in poultry, a nontoxic anticoccidial amount of antibiotic TMB-481 or a salt thereof is administrated to the birds, preferably orally on a daily basis. In case of the oral administration, the compounds of this invention may be supplied with a substance capable of being consumed by the birds, preferably the feed of the birds. The rate of administration, which is effective against infection of coccidiosis, is generally in the range of from about 50 ppm to 250 ppm by weight of unmedicated feed. The compound of this invention may be used optionally together with another anticoccidial agent. The anticoccidial activity of antibiotic TMB-481 is further illustrated by test involving Eimeria tenella in chickens.
For these studies, groups of five 8-day-old chickens were fed a diet containing antibiotic TMB=48l sodium salt at the concentrations of 75 ppm and 125 ppm uniformly dispersed therein. The diet used has the following composition.
47.0% corn 3.0% lucerne meal
10.0% barley four 3.0% sucrose
10.0% defatted rice bran 3.0% CaCO3
10.0% soy bean meal 0.5%- NaCI
7.0% fish meal 0.5% Vitamin premix
7.0% wheat bran
After having been on this ration for 48 hours, each chicken was inoculated with sporulated oocysts of Eimeria tenella. Other groups of five 8-day-old chickens were fed the diet which did not contain antibiotic TMB481 sodium salt. One of these groups was also inolculated with E. tenella after 48 hours and served as infected control. Other of these groups was not inoculated with E. tenella and served as normal control. Medication was continued 7 days after infective oocysts were administrated and then the results of treatment were evaluated.
The chickens were weighed, sacrificed and examined for evidence of coccidial lessions. Coccidial imvolvment was expressed on an arbitrary scale, increasing from minus (no evidence of coccidiosis) to four plus (maximum involvement for E. tenella). The results of the test is shown in Table 2.
TABLE 2
Treatment Fecals Lesion Relative Mortality
scores scores wt. gain ~ # ++ +++ ++++
Non-medicated group, 5 5 0 0 0 0 100 0/5 non infected Non-medicated group. ++ ^ .0 0 0 5 31.4 2/5 infected
Medicated group 75 ppm + I i D 3 0 87.4 0/5
125 ppm - 4 @ 0 0 0 94.3 0/5
Fecal scores -: normal
+: diarrhea
++: blood diarrhea
Lesion scores -: normal
+: insignificant
++: slight degree
+++: middle degree
++++: heavy degree
The antibiotics of this invention also exhibit inhibitory activity against the growth of pathogenic microorganisms, particularly Gram-positive bacteria. The levels at which antibiotic TMB481 sodium salt shows inhibition against the growth of illustrative organisms are set forth in Table 3. The inhibitory levels were determined by the agar dilution test. In the agar dilution test, the test organism was streaked on a series of heart infusion agar plates containing various concentration of antibiotic TMBH81 sodium salt to determine the minimum inhibitory concentration of antibiotic TMB481 sodium salt in mcg/ml(micrograms per milliliter) in the agar substarate which inhibited the growth of the organism over a period of 24 hours.
TABLE 3
Antimicrobial Spectrum of Antibiotic TMB-481 Sodium Salt
Microorganism MIC (mcg/ml)
Staphylococcus aureus 209P 6.25
Staphylococcus aureus Smith 50
Staphylococcus aureus TPR--18 25
Staphylococcus aureus TPR-23 25
Staphylococcus aureus TPR-26 25
Staphylococcus aureus TPR-27 25
Staphylococcus epidermidis TPR-l3 25
Staphylococcus epidermidis TPR- 14 12.5
Staphylococcus epidermidis TPR-16 12.5
Staphylococcus epidermidis TPR-25 12.5
Staphylococcus epidermidis TPR-28 12.5
Bacillus subtilis PCI 219 12.5
Micrococcus luteus NIHJ 12.5
Escherichia coli B > 50
Escherichia coli 055 > 50
Proteus vulgaris HX--19 > 50
Pseudomonas aeruginosa P-32 > 50
Medium: Heart infusion agar
Following is a description by way of example only of methods of carrying the invention into effect.
Example 1.
Shake flask production of antibiotic TMB-481
The production of antibiotic TMB-481 in shake flask cultures is illustrated by the following example:
Spores of Streptomyces ribosidificus TM-481 (ATCC No. 31051) were inoculated on a nutrient agar slant made up of 20 g of oat meal 20 g of agar and
sufficient water to make a total volume of one liter. The slant were inoculated with
spores of Streptomyces ribosidificus TM--481 and incubated for three to four days at 30"C. The slants were covered with sterile distilled water and gently scraped to
remove the organisms and provide an aqueous suspension thereof. One milliliter of the resulting spore suspension was used to inoculate each 100 milliliter portion of the production medium prepared as follows:
The production medium was prepared by combining 10 g of glucose, 20 g of
oat meal, 3 g of meat extract, 3 g of sodium chloride, 2 g of calcium carbonate, 400
mg of ferric sulfate, 400 mg of manganase chloride and sufficient distilled water to
make the total volume one liter and adjusting pH at 7.0 with sodium hydroxide.
One hundred milliliter portion of the production medium were placed in five -hundred milliliter Erlenmeyer flask, which were then sterillized at 1200C for 15
minutes.
The production flasks were shaken for 72 hours at 300 C, on a rotary shaker
operating at 200 r.p.m..
The whole broth (5 liters) obtained by the above precedure, was basified with
sodium hydroxide and was filtered in vacuo with the aid of diatomaceous earth.
The mycelium cake was extracted two time with acetone. The two mycelial
extracts were combined and concentrated in vacuo to remove the acetone. The
filtered broth and aqueous concentrate of the mycelial extract solutions were
combined, and the solution was extracted two times with one-half volume of ethyl
acetate. The ethyl acetate extracts were combined and concentrated to contain 1.5 g
of the crude antibiotic mixture.
Example 2 Pilot plant production of antibiotic TMBH81 The production of antibiotic TMBW81 byisubmerged fermentation on a pilot
scale is illustrated by the following procedure:
Five liters of an aqueous culture medium containing 1% glucose, 2% oat meal, 0.3% meat extract, 0.3% sodium chloride and 0.2% calcium carbonate at pH 7.0 is
divided into 10 parts and each 500 milliliter is poured into a 2 liter Sakaguchi flask.
The medium is sterilized at 1200C for 15 minutes.~ fter coĢ²ling,~~each medium is inoculated with 10 milliliters of culture of Streptomyces ribosidificus TM481 in a 500 milliliter Sakaguchi flask. The culture is shaken for 48 hours at 300 C.
Then, 5 liters of the obtained seed culture is transferred into a 250 liter fermentor containing 200 liters of the same aqueous medium. The culture in the fermentor is aerated and agitated for 60 hours at 300 C.
The crude antibiotic mixture was obtained as brown syrup by the same method as described ..in Example 1 except that centrifugation instead of filtration was carried out to separate the mycelium from the supernatant. Yield: 250 milliliters.
Example 3.
Isolation of antibiotic TOMB481 mixed sodium and potassium salts
All of the crude antibiotic mixture obtained in Example 2 was dissolved in one
liter of benzene, and the insoluble precipitate was removed by filtration with the
aid of filter paper. After the benzene solution was passed through a column packed
with 500 g of silica gel(Wakogel C-200) by the use of benzene, the column was
eluted with one liter of benzene to remove impurities, and eluted with chloroform
until all of antibiotic TM--481 had been collected in the eluate. And then, the column was eluted with chloroform-methanol (99:1) to obtain the objective
compound in the elute fractions. These fractions were combined and evaporated in
vacuo. Six hundred mg of the resulting solid was dissolved in methanol, and further
purified by gel filtration on Sephadex LH-20 by the use of methanol as the eluant.
The fractions containing only the objective compound checked by TLC on silica
gel (Kieselgel 60 F254) in benzene-acetone (2:1) and detected by vanillin-H2SO4, were pooled and evaporated to dryness. The resulting white powder was
crystallized from n-hexane-benzene (4:1) to obtain 400 mg of the objective
compound, antibiotic TMB--481 mixed sodium and potassium salts, as colorless
needles.
Example 4,
Preparation of antibiotic TMBC81 and its sodium salt
To 100 mg of antibiotic TMB--481 mixed sodium and potassium salt obtained in Example 3, 10 milliliters of acetone was added. To the resulting solution, one drop of 1 N HCI and 5 milliliters of water were added. The solution was extracted three times with 5 milliliters of benzene. The extracts were combined, washed with water and evaporated in vacuo to give 85 mg of the free acid of antibiotic TMB "81 as powder. The powder thus obtained was dissolved in 5 milliliters of acetone. To the resulting solution, 7.5 milliliters of water and one drop of 5 N
NaOH were added. The extracts were combined, evaporated and crystallized with the same method as described in Example 3 to give 75 mg of antibiotic TM B--48 I sodium salt.
Claims (4)
- WHAT WE CLAIM IS: I. An antibiotic TMB--481 represented by the formulaand its alkali metal salts.
- 2. A method for the production of antibiotic TMB-481 and its alkali metal salts which comprises cultivating the microorganism strain Streptomyces ribosidificus TM481(ATCC No. 31051) in a culture medium containing assimilable carbon and nitrogen sources, extracting antibiotic TMBH81 thus obtained from the culture medium with an organic solvent and separating TMB-481 from the extract solution as such or as an alkali metal salt.
- 3. An antibiotic as claimed in Claim 1 and substantially as described in any one of the specific examples hereinbefore set forth.
- 4. A method of producing an antibiotic as claimed in Claim 1 substantially as herein described with reference to the accompanying drawings or in the specific examples hereinbefore set forth.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5055477A JPS53135902A (en) | 1977-04-30 | 1977-04-30 | Antibiotic tmb-481 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1587089A true GB1587089A (en) | 1981-03-25 |
Family
ID=12862226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB15258/78A Expired GB1587089A (en) | 1977-04-30 | 1978-04-18 | Poly-ether antibiotics |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPS53135902A (en) |
GB (1) | GB1587089A (en) |
-
1977
- 1977-04-30 JP JP5055477A patent/JPS53135902A/en active Pending
-
1978
- 1978-04-18 GB GB15258/78A patent/GB1587089A/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
JPS53135902A (en) | 1978-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4530835A (en) | CL-1577 Antibiotic compounds and their production | |
US5278052A (en) | Process for the simultaneous production of benanomicins A and B | |
US4578271A (en) | Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions | |
US5013550A (en) | Antibiotics called "chloropolysporins B and C", a process for their preparation, and their therapeutic and veterinary use | |
US4539203A (en) | CL-1577D And CL-1577E antibiotic/antitumor compounds, their production and use | |
EP0194784B1 (en) | Cl-1577-b4 compound, its production and use | |
SU867318A3 (en) | Method of preparing baumycin a and b | |
US4536398A (en) | Antiviral agents | |
US3950514A (en) | Antibiotic TM-481 derived from microorganism of the streptomyces ribosidificus group | |
US4264607A (en) | A40A Efrotomycin-like antibiotic in fermentation broth | |
US4174404A (en) | Deoxynarasin antibiotics | |
US4792522A (en) | Rigolettone antitumor complex | |
US4226879A (en) | Antibiotic composition | |
US4598145A (en) | Albacarcins V and M | |
US4110435A (en) | Antibiotic a-28086 factor d and process for production thereof | |
US4110436A (en) | Antibiotic a-28086 factor d and process for production thereof | |
US4503152A (en) | Process for preparing antibiotic AM-2604-A | |
US5109122A (en) | Antibiotics, dexylosylbenanomicin B | |
EP0053025B1 (en) | Antibiotic and its preparation from a streptomyces microorganism | |
NO132242B (en) | ||
GB1587089A (en) | Poly-ether antibiotics | |
US4565781A (en) | Antibiotic, Spicamycin | |
US4003902A (en) | Naphthyridinomycin antibiotics | |
US4262002A (en) | Discovery of A73A, a new efrotomycin-like antibiotic in fermentation broth | |
US4615975A (en) | Purified culture of Actinomadura verrucaspora subspecies veractimyces |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed [section 19, patents act 1949] | ||
PCNP | Patent ceased through non-payment of renewal fee |